| pubmed-article:9419437 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:9419437 | lifeskim:mentions | umls-concept:C0004364 | lld:lifeskim |
| pubmed-article:9419437 | lifeskim:mentions | umls-concept:C0021083 | lld:lifeskim |
| pubmed-article:9419437 | lifeskim:mentions | umls-concept:C0034790 | lld:lifeskim |
| pubmed-article:9419437 | lifeskim:mentions | umls-concept:C0030956 | lld:lifeskim |
| pubmed-article:9419437 | pubmed:issue | 5-6 | lld:pubmed |
| pubmed-article:9419437 | pubmed:dateCreated | 1998-2-25 | lld:pubmed |
| pubmed-article:9419437 | pubmed:abstractText | The observations in both mouse and rat models of experimental allergic encephalomyelitis (EAE) demonstrating restricted T-cell receptor (TCR) usage among pathogenic T cells has led to the generation of a new class of therapeutic vaccines composed of TCR V region peptides. Whether a similar approach will be of use in the treatment of human autoimmune disorders is still unclear. The experiments performed in our laboratory over the past several years have focused on two aspects of TCR peptide immunoregulation, namely, (1) how to identify the critical T-cell populations involved in the pathology of autoimmune disease, and (2) how to identify biologically relevant TCR peptides--those endogenous TCR peptides presented in association with MHC molecules on the surface of pathogenic T cells that are recognized by immunoregulatory T-cell populations. Results of our recently completed clinical studies regarding TCR V beta expression among CD4+ T cells in the cerebral spinal fluid (CSF) of patients with multiple sclerosis suggests that these cells may be an appropriate T-cell population to be targeted for TCR peptide therapy. In addition, our studies on the immune response to autologous, soluble TCR heterodimers may provide a strategy for the identification of new TCR peptide candidate vaccines. | lld:pubmed |
| pubmed-article:9419437 | pubmed:language | eng | lld:pubmed |
| pubmed-article:9419437 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9419437 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:9419437 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9419437 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9419437 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:9419437 | pubmed:issn | 1040-8401 | lld:pubmed |
| pubmed-article:9419437 | pubmed:author | pubmed-author:WilsonD BDB | lld:pubmed |
| pubmed-article:9419437 | pubmed:author | pubmed-author:BrostoffS WSW | lld:pubmed |
| pubmed-article:9419437 | pubmed:author | pubmed-author:GoldingAA | lld:pubmed |
| pubmed-article:9419437 | pubmed:author | pubmed-author:GoldD PDP | lld:pubmed |
| pubmed-article:9419437 | pubmed:author | pubmed-author:ShroederKK | lld:pubmed |
| pubmed-article:9419437 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:9419437 | pubmed:volume | 17 | lld:pubmed |
| pubmed-article:9419437 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:9419437 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:9419437 | pubmed:pagination | 507-10 | lld:pubmed |
| pubmed-article:9419437 | pubmed:dateRevised | 2005-11-16 | lld:pubmed |
| pubmed-article:9419437 | pubmed:meshHeading | pubmed-meshheading:9419437-... | lld:pubmed |
| pubmed-article:9419437 | pubmed:meshHeading | pubmed-meshheading:9419437-... | lld:pubmed |
| pubmed-article:9419437 | pubmed:meshHeading | pubmed-meshheading:9419437-... | lld:pubmed |
| pubmed-article:9419437 | pubmed:meshHeading | pubmed-meshheading:9419437-... | lld:pubmed |
| pubmed-article:9419437 | pubmed:meshHeading | pubmed-meshheading:9419437-... | lld:pubmed |
| pubmed-article:9419437 | pubmed:meshHeading | pubmed-meshheading:9419437-... | lld:pubmed |
| pubmed-article:9419437 | pubmed:meshHeading | pubmed-meshheading:9419437-... | lld:pubmed |
| pubmed-article:9419437 | pubmed:meshHeading | pubmed-meshheading:9419437-... | lld:pubmed |
| pubmed-article:9419437 | pubmed:meshHeading | pubmed-meshheading:9419437-... | lld:pubmed |
| pubmed-article:9419437 | pubmed:meshHeading | pubmed-meshheading:9419437-... | lld:pubmed |
| pubmed-article:9419437 | pubmed:meshHeading | pubmed-meshheading:9419437-... | lld:pubmed |
| pubmed-article:9419437 | pubmed:year | 1997 | lld:pubmed |
| pubmed-article:9419437 | pubmed:articleTitle | T-cell receptor peptides as immunotherapy for autoimmune disease. | lld:pubmed |
| pubmed-article:9419437 | pubmed:affiliation | Sidney Kimmel Cancer Center, San Diego, CA 92121, USA. | lld:pubmed |
| pubmed-article:9419437 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:9419437 | pubmed:publicationType | Review | lld:pubmed |
